Fractionated radiotherapy with 3 x 8 Gy induces systemic anti-tumour responses and abscopal tumour inhibition without modulating the humoral anti-tumour response

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Habets, Thomas H P M ^a   Oth, Tammy ^a   Houben, Ans W ^a,b   Huijskens, Mirelle J A J ^a   Senden Gijsbers, Birgit L M G ^a   Schnijderberg, Melanie C A ^a   Brans, Boudewijn ^b   Dubois, Ludwig J ^a   Lambin, Philippe ^a   De Saint Hubert, Marijke ^b   Germeraad, Wilfred T V ^a,c   Tilanus, Marcel G J ^a   Mottaghy, Felix M ^b   Bos, Gerard M J ^a,c   Vanderlocht, Joris ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CiMaas BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; FLT3 LIGAND PROTEIN; IMMUNOGLOBULIN CLASS; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; GAMMA RADIATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIMARY TUMOR; RADIATION RESPONSE; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR REGRESSION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; CARCINOMA; FEMALE; IMMUNOLOGY; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY; RADIATION DOSE FRACTIONATION; T LYMPHOCYTE; THERAPEUTIC USE; UDDER;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA; DENDRITIC CELLS; DOSE FRACTIONATION; FEMALE; GAMMA RAYS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN ISOTYPES; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES;

EID: 84979277031     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159515     Document Type: Article

References (44)

1. Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Frontiers in oncology. 2012; 2:153. doi: 10.3389/fonc.2012.00153 PMID: 23112958
2. Formenti SC, Demaria S. Systemic effects of local radiotherapy. The lancet oncology. 2009; 10(7):718-26. doi: 10.1016/S1470-2045(09)70082-8 PMID: 19573801
3. Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Science translational medicine. 2013; 5(173):173sr2. doi: 10.1126/scitranslmed.3005148 PMID: 23427246
4. Mole RH. Whole body irradiation; radiobiology or medicine? The British journal of radiology. 1953; 26(305):234-41. PMID: 13042090
5. Kaminski JM, Shinohara E, Summers JB, Niermann KJ, Morimoto A, Brousal J. The controversial abscopal effect. Cancer treatment reviews. 2005; 31(3):159-72. PMID: 15923088
6. Siva S, Macmanus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: A clinical review for the radiobiologist. Cancer letters. 2013.
7. Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Current problems in cancer. 2015.
8. Bramhall RJ, Mahady K, Peach AH. Spontaneous regression of metastatic melanoma - clinical evidence of the abscopal effect. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2014; 40(1):34-41.
9. Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014; 3:e28780. PMID: 25083318
10. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. The New England journal of medicine. 2012; 366(10):925-31. doi: 10.1056/NEJMoa1112824 PMID: 22397654
11. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. International journal of radiation oncology, biology, physics. 2013; 85(2):293-5. doi: 10.1016/j.ijrobp.2012.03.017 PMID: 22560555
12. Sullivan RJ, Lawrence DP, Wargo JA, Oh KS, Gonzalez RG, Piris A. Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. The New England journal of medicine. 2013; 369(2):173-83. doi: 10.1056/NEJMcpc1302332 PMID: 23841733
13. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer immunology research. 2013; 1(6):365-72. doi: 10.1158/2326-6066.CIR-13-0115 PMID: 24563870
14. Okuma K, Yamashita H, Niibe Y, Hayakawa K, Nakagawa K. Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: a case report. Journal of medical case reports. 2011; 5:111. doi: 10.1186/1752-1947-5-111 PMID: 21418591
15. Wersall PJ, Blomgren H, Pisa P, Lax I, Kalkner KM, Svedman C. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta oncologica. 2006; 45(4):493-7. PMID: 16760190
16. Ohba K, Omagari K, Nakamura T, Ikuno N, Saeki S, Matsuo I, et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut. 1998; 43(4):575-7. PMID: 9824589
17. Lakshmanagowda PB, Viswanath L, Thimmaiah N, Dasappa L, Supe SS, Kallur P. Abscopal effect in a patient with chronic lymphocytic leukemia during radiation therapy: a case report. Cases journal. 2009; 2:204. doi: 10.1186/1757-1626-2-204 PMID: 19946448
18. Golden EB, Apetoh L. Radiotherapy and Immunogenic Cell Death. Seminars in radiation oncology. 2015; 25(1):11-7. doi: 10.1016/j.semradonc.2014.07.005 PMID: 25481261
19. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, et al. Immunogenic cancer cell death: a key-lock paradigm. Current opinion in immunology. 2008; 20(5):504-11. doi: 10.1016/j.coi.2008.05.007 PMID: 18573340
20. Kono K, Mimura K, Kiessling R. Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell death & disease. 2013; 4:e688.
21. Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Frontiers in oncology. 2014; 4:325. doi: 10.3389/fonc.2014.00325 PMID: 25506582
22. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. Journal of the National Cancer Institute. 2013; 105(4):256-65. doi: 10.1093/jnci/djs629 PMID: 23291374
23. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. International journal of radiation oncology, biology, physics. 2004; 58(3):862-70. PMID: 14967443
24. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(17):5379-88.
25. Chakravarty PK, Alfieri A, Thomas EK, Beri V, Tanaka KE, Vikram B, et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer research. 1999; 59(24):6028-32. PMID: 10626784
26. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(8):3539-43. PMID: 8097319
27. Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. The lancet oncology. 2015; 16(7):795-803. doi: 10.1016/S1470-2045(15)00054-6 PMID: 26095785
28. Girit IC, Jure-Kunkel M, McIntyre KW. A structured light-based system for scanning subcutaneous tumors in laboratory animals. Comp Med. 2008; 58(3):264-70. PMID: 18589868
29. Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(50):21248-55. doi: 10.1073/pnas.1015855107 PMID: 21081700
30. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer research. 1992; 52(6):1399-405. PMID: 1540948
31. Smith KM, Pottage L, Thomas ER, Leishman AJ, Doig TN, Xu D, et al. Th1 and Th2 CD4+ T cells provide help for B cell clonal expansion and antibody synthesis in a similar manner in vivo. Journal of immunology. 2000; 165(6):3136-44.
32. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nature medicine. 1997; 3(6):625-31. PMID: 9176488
33. Melero I, Berman DM, Aznar MA, Korman AJ, Perez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015; 15(8):457-72. doi: 10.1038/nrc3973 PMID: 26205340
34. Spiegelberg HL. Biological activities of immunoglobulins of different classes and subclasses. Adv Immunol. 1974; 19(0):259-94. PMID: 4611173
35. Greenberg AH, Shen L, Medley G. Characteristics of the effector cells mediating cytotoxicity against antibody-coated target cells. I. Phagocytic and non-phagocytic effector cell activity against erythrocyte and tumour target cells in a 51Cr release cytotoxicity assay and [125I]IUdR growth inhibition assay. Immunology. 1975; 29(4):719-29. PMID: 810417
36. Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proceedings of the National Academy of Sciences of the United States of America. 1982; 79(15):4761-5. PMID: 6289317
37. Pio R, Corrales L, Lambris JD. The role of complement in tumor growth. Adv Exp Med Biol. 2014; 772:229-62. doi: 10.1007/978-1-4614-5915-6-11 PMID: 24272362
38. Derer A, Deloch L, Rubner Y, Fietkau R, Frey B, Gaipl US. Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol. 2015; 6:505. doi: 10.3389/fimmu.2015.00505 PMID: 26500646
39. Derer A, Frey B, Fietkau R, Gaipl US. Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer immunology, immunotherapy: CII. 2015.
40. Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013; 93(6):847-63. doi: 10.1189/jlb.1012501 PMID: 23475577
41. Blank CU. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr Opin Oncol. 2014; 26(2):204-14. doi: 10.1097/CCO.0000000000000054 PMID: 24424272
42. Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM. Immuno-regulatory antibodies for the treatment of cancer. Expert Opin Biol Ther. 2015; 15(6):787-801. doi: 10.1517/14712598.2015.1036737 PMID: 25882106
43. Blank CU, Enk A. Therapeutic use of anti-CTLA-4 antibodies. Int Immunol. 2015; 27(1):3-10. doi: 10.1093/intimm/dxu076 PMID: 25038057
44. Ito A, Kondo S, Tada K, Kitano S. Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int. 2015; 2015:605478. doi: 10.1155/2015/605478 PMID: 26161407